Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2155-2157

  Tobin, C M ^a   Lovering, A M ^a   Sweeney, E ^a   MacGowan, A P ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Glycopeptides; Patients; Pharmacokinetics

Indexed keywords

TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG DETERMINATION; DRUG MONITORING; ENDOCARDITIS; GRAM POSITIVE INFECTION; HEALTH SERVICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRESCHOOL CHILD; SCHOOL CHILD; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SERUM; TEICOPLANIN; TIME FACTORS; YOUNG ADULT;

EID: 77957230272     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq266     Document Type: Article

References (12)

1. Barrett JF. Recent developments in glycopeptide antibacterials. Curr Opin Investig Drugs 2005; 6: 781-90.
2. Outman WR, Nightingale CH, Sweeney KR et al. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother 1990; 34: 2114-7.
3. Wilson APR, Grüneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993; 32: 792-6.
4. Sato M, Chida K, Suda T et al. Recommended initial loading dose of teicoplanin, established by optimal drug monitoring and outcome in terms of optimal trough level. J Infect Chemother 2006; 12: 185-9.
5. Davey PG, William AH. Teicoplanin monotherapy of serious infections caused by Gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial. J Antimicrob Chemother 1991; 27 Suppl B: 51-60.
6. Weinbren M, Struthers K. Emergence of Staphylococcus aureus with reduced susceptibility to teicoplanin during therapy. J Antimicrob Chemother 2002; 50: 306-7.
7. Pea F, Brollo L, Viale P et al. Teicoplanin optimal drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51: 971-5.
8. Harding I, MacGowan AP, White LO et al. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between trough serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835-41.
9. British National Formulary, 58, September 2009. London: BMJ Publishing Group.
10. Gemmell CG, Edwards DI, Fraise AP. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 5: 589-608.
11. Joos B, Luthy R. Determination of teicoplanin concentrations in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother 1987; 31: 1222-4.
12. Lamont E, Seaton EA, Macpherson M et al. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother 2009; 64: 181-7.